Biodesix provides end-to-end diagnostic and biomarker development services for biopharmaceutical, life sciences, and research organizations, supporting programs from early translational research and biomarker discovery through assay development, clinical validation, regulatory submission, and commercialization.
The company takes a multi-omic approach, combining genomic and proteomic technologies to answer complex questions across clinical development. Capabilities include cfDNA and cfRNA testing, liquid biopsy, ddPCR and next-generation sequencing, discovery and targeted proteomics, clinical trial sample testing, custom assay development and validation, and sample logistics. Biodesix also supports applications such as patient selection, treatment-response monitoring, minimal residual disease, PK/PD studies, and companion diagnostic development.
Biodesix operates two highly accredited U.S. laboratories and brings firsthand experience developing and commercializing its own clinical diagnostic tests. Its infrastructure supports regulated development programs with capabilities spanning laboratory testing, quality systems, specimen collection and transport, regulatory documentation, reimbursement strategy, and commercialization. Biodesix has worked with more than 65 industry and academic partners, including 8 of the top 10 pharmaceutical companies.
